64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression

被引：5
|
作者：
Lee, Inki [1 ]
Lim, Ilhan [1 ,2 ,3 ,6 ]
Lee, Kyo Chul [2 ]
Kang, Hye Jin [4 ,5 ]
Lim, Sang Moo [1 ]
机构：
[1] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Nucl Med, Seoul, South Korea
[2] Korea Inst Radiol & Med Sci, Res Inst Radiol & Med Sci, Div Appl RI, Seoul, South Korea
[3] Univ Sci & Technol, Dept Radiol & Med Oncol Sci, Seoul, South Korea
[4] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea
[5] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, 75,Nowon Ro, Seoul, South Korea
[6] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Nucl Med, 75,Nowon Ro, Seoul, South Korea
来源：
CLINICAL NUCLEAR MEDICINE | 2023年 / 48卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
Cu-64-DOTA-rituximab; B-cell lymphoma; CD20; antigen; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET;
D O I：
10.1097/RLU.0000000000004378
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Cu-64-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with F-18-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible Cu-64-DOTA-rituximab uptake in the tumor other than lymphoma. Cu-64-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.
引用
收藏
页码：E82 / E83
页数：2
相关论文
共 50 条
  • [1] Validation of 64Cu-DOTA-Rituximab Injection Preparation Under Good Manufacturing Practices: A PET Tracer for Imaging of B-Cell Non-Hodgkin Lymphoma
    Natarajan, Arutselvan
    Arksey, Natasha
    Iagaru, Andrei
    Chin, Frederick T.
    Gambhir, Sanjiv Sam
    MOLECULAR IMAGING, 2015, 14
  • [2] Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
    Tsai, Ping-Chiao
    Hernandez-Ilizaliturri, Francisco J.
    Bangia, Naveen
    Olejniczak, Scott H.
    Czuczman, Myron S.
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1039 - 1050
  • [3] CD20 mutation is associated with resistance to rituximab in a subset of patients with B-cell non-Hodgkin lymphoma
    Libra, Massimo
    Terzo, Maria N.
    Militello, Loredana
    Russo, Alessia E.
    Ligresti, Giovanni
    Russo, Mario
    Nicoletti, Ferdinando
    Stivala, Franca
    Bonavida, Benjamin
    Travali, Salvatore
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S66 - S66
  • [4] Immuno-PET Imaging for CD20 Expression in Non-Hodgkin's Lymphoma
    Bozkir, E. T. Sarcan
    Paisey, S.
    Ruthardt, M.
    Ozer, A. Y.
    Marshall, C.
    Hartman, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S435 - S435
  • [5] Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Marshalek, Joseph P.
    Qing, Xin
    Dragan, Marcin
    Tomassetti, Sarah
    JOURNAL OF HEMATOLOGY, 2024, 13 (06) : 268 - 277
  • [6] Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab
    Chul-Hee Lee
    Ilhan Lim
    Sang-Keun Woo
    Wook Kim
    Kwang Il Kim
    Kyo Chul Lee
    Kanghyon Song
    Sang Moo Lim
    Annals of Nuclear Medicine, 2021, 35 : 639 - 647
  • [7] The feasibility of targeted imaging of 64Cu-DOTA-rituximab PET in a xenograft model of human lymphoma
    Lee, Chul-Hee
    Kim, Kwang Il
    Woo, Sang-Keun
    Kang, Choong Mo
    Lee, Kyo Chul
    Lee, Inki
    Byun, Byung Hyun
    Kim, Byung Il
    Choi, Chang Woon
    Song, Kanghyon
    Lim, Sang Moo
    Lim, Ilhan
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [8] Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab
    Lee, Chul-Hee
    Lim, Ilhan
    Woo, Sang-Keun
    Kim, Wook
    Kim, Kwang Il
    Lee, Kyo Chul
    Song, Kanghyon
    Lim, Sang Moo
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (05) : 639 - 647
  • [9] Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
    Hernandez, MC
    Knox, SJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1274 - 1287
  • [10] Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
    Sacchi, S
    Federico, M
    Dastoli, G
    Fiorani, C
    Vinci, G
    Clò, V
    Casolari, B
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 13 - 25
12345